Base de dados : MEDLINE
Pesquisa : E05.318.308.985.775 [Categoria DeCS]
Referências encontradas : 8716 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 872 ir para página                         

  1 / 8716 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28455751
[Au] Autor:Hipp H; Crawford S; Kawwass JF; Boulet SL; Grainger DA; Kissin DM; Jamieson D
[Ad] Endereço:Division of Reproductive Endocrinology and Infertility, Emory University School of Medicine, Emory University, 550 Peachtree Street, Suite 1800, Atlanta, GA, 30308, USA. hhipp@emory.edu.
[Ti] Título:National trends and outcomes of autologous in vitro fertilization cycles among women ages 40 years and older.
[So] Source:J Assist Reprod Genet;34(7):885-894, 2017 Jul.
[Is] ISSN:1573-7330
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The purpose of the study was to describe trends in and investigate variables associated with clinical pregnancy and live birth in autologous in vitro fertilization (IVF) cycles among women ≥40 years. METHODS: We used autologous IVF cycle data from the National ART Surveillance System (NASS) for women ≥40 years at cycle start. We assessed trends in fresh and frozen cycles (n = 371,536) from 1996 to 2013. We reported perinatal outcomes and determined variables associated with clinical pregnancy and live birth in fresh cycles between 2007 and 2013. RESULTS: From 1996 to 2013, the total number of cycles in women ≥40 years increased from 8672 to 28,883 (p < 0.0001), with frozen cycles almost tripling in the last 8 years. Cycles in women ≥40 years accounted for 16.0% of all cycles in 1996 and 21.0% in 2013 (p < 0.0001). For fresh cycles from 2007 to 2013 (n = 157,890), the cancelation rate was 17.1%. Among cycles resulting in transfer (n = 112,414), the live birth rate was 16.1%. The following were associated with higher live birth rates: multiparity, fewer prior ART cycles, use of standard agonist or antagonist stimulation, lower gonadotropin dose, ovarian hyperstimulation syndrome, more oocytes retrieved, use of pre-implantation genetic screening/diagnosis, transferring more and/or blastocyst stage embryos, and cryopreserving more supernumerary embryos. Of the singleton infants born (n = 14,992), 86.9% were full term and 88.3% normal birth weight. CONCLUSIONS: The NASS allows for a comprehensive description of IVF cycles in women ≥40 years in the USA. Although live birth rate is less than 20%, identifying factors associated with IVF success can facilitate treatment option counseling.
[Mh] Termos MeSH primário: Fertilização In Vitro/tendências
Taxa de Gravidez
[Mh] Termos MeSH secundário: Adulto
Fatores Etários
Centers for Disease Control and Prevention (U.S.)
Feminino
Fertilização In Vitro/estatística & dados numéricos
Seres Humanos
Infertilidade/terapia
Gravidez
Resultado do Tratamento
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE
[do] DOI:10.1007/s10815-017-0926-2


  2 / 8716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29424977
[Au] Autor:Santibáñez-Morales A; Durán-Boullosa E; Colín-Licea EO
[Ti] Título:[Use of growth hormone for in vitro fertilization].
[Ti] Título:Indicación de hormona de crecimiento en ciclos de fertilización in vitro..
[So] Source:Ginecol Obstet Mex;84(9):567-72, 2016 Sep.
[Is] ISSN:0300-9041
[Cp] País de publicação:Mexico
[La] Idioma:spa
[Ab] Resumo:Background: Ovarian stimulation is the cornerstone in fertility treatments, it produces multifolicular development and in consequence, a greater pregnancy rate. Poor responder patients have bad outcomes in IVF, several medical approaches have been proposed in managing these patients, including Growth Hormone. Objetive: To report our results with the use of growth hormone and review published data. Material and method: Case series conducted from January 2013 to May 2015 in patients to Centro de Reproducción PROCREA, Mexico City, poor responders according to the criteria of consensus Bologna cycles in fresh stimulation protocol Flare up, application of growth hormone as adjuvant, complete cycles of stimulation (stimulation, oocyte capture, and embryo transfer pregnancy test) and complete records. For statistical analysis, averages and percentages were used. Results: 40 cases were analyzed. Age and BMI were 39.1 ± 2.1 years and 24.6 ± 2.8 kg/m2, respectively. Total gonadotrophin dose was 2128.6 ± 1078.9 UI, retrieved oocytes and fertilized eggs were 7.1 ± 4.0 y 5.4 ± 2.8 respectively. Fertilization rate was 76.3% and pregnancy rate was 59.5%. Conclusion: There is insufficient evidence for prescribing GH in all patients requiring IVF, nevertheless, in poor responder patients, there seems to be an improvement in egg quality leading to better fertilization and pregnancy rate, with no adverse effects.
[Mh] Termos MeSH primário: Fertilização In Vitro/métodos
Hormônio do Crescimento/administração & dosagem
Indução da Ovulação/métodos
[Mh] Termos MeSH secundário: Adulto
Feminino
Gonadotropinas/administração & dosagem
Seres Humanos
México
Gravidez
Taxa de Gravidez
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Gonadotropins); 9002-72-6 (Growth Hormone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE


  3 / 8716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29368795
[Au] Autor:Kop PA; Mochtar MH; O'Brien PA; Van der Veen F; van Wely M
[Ad] Endereço:Obstetrics and Gynaecology, Center for Reproductive Medicine, Academic Medical Centre, Meibergdreef 9, Amsterdam, Netherlands, 1105 AZ.
[Ti] Título:Intrauterine insemination versus intracervical insemination in donor sperm treatment.
[So] Source:Cochrane Database Syst Rev;1:CD000317, 2018 01 25.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The first-line treatment in donor sperm treatment consists of inseminations that can be done by intrauterine insemination (IUI) or by intracervical insemination (ICI). OBJECTIVES: To compare the effectiveness and safety of intrauterine insemination (IUI) and intracervical insemination (ICI) in women who start donor sperm treatment. SEARCH METHODS: We searched the Cochrane Gynaecology and Fertility Group Trials Register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL in October 2016, checked references of relevant studies, and contacted study authors and experts in the field to identify additional studies. We searched PubMed, Google Scholar, the Grey literature, and five trials registers on 15 December 2017. SELECTION CRITERIA: We included randomised controlled trials (RCTs) reporting on IUI versus ICI in natural cycles or with ovarian stimulation, and RCTs comparing different cointerventions in IUI and ICI. We included cross-over studies if pre-cross-over data were available. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures recommended by Cochrane. We collected data on primary outcomes of live birth and multiple pregnancy rates, and on secondary outcomes of clinical pregnancy, miscarriage, and cancellation rates. MAIN RESULTS: We included six RCTs (708 women analysed) on ICI and IUI in donor sperm treatment. Two studies compared IUI and ICI in natural cycles, two studies compared IUI and ICI in gonadotrophin-stimulated cycles, and two studies compared timing of IUI and ICI. There was very low-quality evidence; the main limitations were risk of bias due to poor reporting of study methods, and serious imprecision.IUI versus ICI in natural cyclesThere was insufficient evidence to determine whether there was any clear difference in live birth rate between IUI and ICI in natural cycles (odds ratio (OR) 3.24, 95% confidence interval (CI) 0.12 to 87.13; 1 RCT, 26 women; very low-quality evidence). There was only one live birth in this study (in the IUI group). IUI resulted in higher clinical pregnancy rates (OR 6.18, 95% CI 1.91 to 20.03; 2 RCTs, 76 women; I² = 48%; very low-quality evidence).No multiple pregnancies or miscarriages occurred in this study.IUI versus ICI in gonadotrophin-stimulated cyclesThere was insufficient evidence to determine whether there was any clear difference in live birth rate between IUI and ICI in gonadotrophin-stimulated cycles (OR 2.55, 95% CI 0.72 to 8.96; 1 RCT, 43 women; very low-quality evidence). This suggested that if the chance of a live birth following ICI in gonadotrophin-stimulated cycles was assumed to be 30%, the chance following IUI in gonadotrophin-stimulated cycles would be between 24% and 80%. IUI may result in higher clinical pregnancy rates than ICI (OR 2.83, 95% CI 1.38 to 5.78; 2 RCTs, 131 women; I² = 0%; very low-quality evidence). IUI may be associated with higher multiple pregnancy rates than ICI (OR 2.77, 95% CI 1.00 to 7.69; 2 RCTs, 131 women; I² = 0%; very low-quality evidence). This suggested that if the risk of multiple pregnancy following ICI in gonadotrophin-stimulated cycles was assumed to be 10%, the risk following IUI would be between 10% and 46%.We found insufficient evidence to determine whether there was any clear difference between the groups in miscarriage rates in gonadotrophin-stimulated cycles (OR 1.97, 95% CI 0.43 to 9.04; 2 RCTs, overall 67 pregnancies; I² = 50%; very low-quality evidence).Timing of IUI and ICIWe found no studies that reported on live birth rates.We found a higher clinical pregnancy rate when IUI was timed one day after a rise in blood levels of luteinising hormone (LH) compared to IUI two days after a rise in blood levels of LH (OR 2.00, 95% CI 1.14 to 3.53; 1 RCT, 351 women; low-quality evidence). We found insufficient evidence to determine whether there was any clear difference in clinical pregnancy rates between ICI timed after a rise in urinary levels of LH versus a rise in basal temperature plus cervical mucus scores (OR 1.31, 95% CI 0.42 to 4.11; 1 RCT, 56 women; very low-quality evidence).Neither of these studies reported multiple pregnancy or miscarriage rates as outcomes. AUTHORS' CONCLUSIONS: There was insufficient evidence to determine whether there was a clear difference in live birth rates between IUI and ICI in natural or gonadotrophin-stimulated cycles in women who started with donor sperm treatment. There was insufficient evidence available for the effect of timing of IUI or ICI on live birth rates. Very low-quality data suggested that in gonadotrophin-stimulated cycles, ICI may be associated with a higher clinical pregnancy rate than IUI, but also with a higher risk of multiple pregnancy rate. We concluded that the current evidence was too limited to choose between IUI or ICI, in natural cycles or with ovarian stimulation, in donor sperm treatment.
[Mh] Termos MeSH primário: Inseminação Artificial Heteróloga/métodos
[Mh] Termos MeSH secundário: Temperatura Corporal
Muco do Colo Uterino
Feminino
Gonadotropinas/uso terapêutico
Seres Humanos
Nascimento Vivo/epidemiologia
Hormônio Luteinizante/sangue
Ciclo Menstrual/efeitos dos fármacos
Gravidez
Taxa de Gravidez
Gravidez Múltipla
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Gonadotropins); 9002-67-9 (Luteinizing Hormone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD000317.pub4


  4 / 8716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:29320655
[Au] Autor:Vuong LN; Dang VQ; Ho TM; Huynh BG; Ha DT; Pham TD; Nguyen LK; Norman RJ; Mol BW
[Ad] Endereço:From the Department of Obstetrics and Gynecology, University of Medicine and Pharmacy at Ho Chi Minh City (L.N.V.), IVFMD, My Duc Hospital (L.N.V., V.Q.D., T.M.H., B.G.H., T.D.P., L.K.N.), and the Research Center for Genetics and Reproductive Health, School of Medicine, Vietnam National University (
[Ti] Título:IVF Transfer of Fresh or Frozen Embryos in Women without Polycystic Ovaries.
[So] Source:N Engl J Med;378(2):137-147, 2018 01 11.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Among women who are undergoing in vitro fertilization (IVF), the transfer of frozen embryos has been shown to result in a higher rate of live birth than the transfer of fresh embryos in those with infertility associated with the polycystic ovary syndrome. It is not known whether frozen-embryo transfer results in similar benefit in women with infertility that is not associated with the polycystic ovary syndrome. METHODS: We randomly assigned 782 infertile women without the polycystic ovary syndrome who were undergoing a first or second IVF cycle to receive either a frozen embryo or a fresh embryo on day 3. In the frozen-embryo group, all grade 1 and 2 embryos had been cryopreserved, and a maximum of two embryos were thawed on the day of transfer in the following cycle. In the fresh-embryo group, a maximum of two fresh embryos were transferred in the stimulated cycle. The primary outcome was ongoing pregnancy after the first embryo transfer. RESULTS: After the first completed cycle, ongoing pregnancy occurred in 142 of 391 women (36.3%) in the frozen-embryo group and in 135 of 391 (34.5%) in the fresh-embryo group (risk ratio in the frozen-embryo group, 1.05; 95% confidence interval [CI], 0.87 to 1.27; P=0.65). Rates of live birth after the first transfer were 33.8% and 31.5%, respectively (risk ratio, 1.07; 95% CI, 0.88 to 1.31). CONCLUSIONS: Among infertile women without the polycystic ovary syndrome who were undergoing IVF, the transfer of frozen embryos did not result in significantly higher rates of ongoing pregnancy or live birth than the transfer of fresh embryos. (Funded by My Duc Hospital; ClinicalTrials.gov number, NCT02471573 .).
[Mh] Termos MeSH primário: Criopreservação
Transferência Embrionária
Fertilização In Vitro
Infertilidade Feminina
Taxa de Gravidez
[Mh] Termos MeSH secundário: Adulto
Transferência Embrionária/métodos
Feminino
Seres Humanos
Recém-Nascido
Análise de Intenção de Tratamento
Nascimento Vivo
Indução da Ovulação
Síndrome do Ovário Policístico
Gravidez
Complicações na Gravidez
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180111
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMoa1703768


  5 / 8716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390524
[Au] Autor:Kim SH; Jo J; Kim DI
[Ad] Endereço:Graduate School of Korean Medicine, Dongguk University, Gyeongju.
[Ti] Título:The effectiveness, safety, and economic evaluation of Korean medicine for unexplained infertile women: A multi-center, prospective, observational study protocol.
[So] Source:Medicine (Baltimore);96(51):e9360, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Infertility is a condition in which a woman has not been pregnant despite having had normal intercourse for 1 year. The number of unexplained infertile females is increasing because of late marriage customs, as well as environmental and lifestyle habits. In Korea, infertile females have been treated with Korean medicine (KM). However, these effects have not been objectively confirmed through clinical trials. Therefore, this study was conducted to demonstrate the effectiveness of herbal medicine treatment in infertile patients and to demonstrate the economic feasibility through economical evaluation with assisted reproductive technology.This study is designed as a multicenter, single-arm clinical trial. All participants included will be from 3 Korean Medicine hospitals in Korea and will voluntarily sign an informed consent agreement. All recruited patients will conduct related surveys and tests, and be provided with treatment according to their menstrual cycle. Patients will take herbal medicines for 4 menstruation cycles and receive acupuncture and moxibustion treatment at 3 times (menstrual cycle day 3, 8, 14) during 4 menstruation cycles. They will also undergo an approximately 4 menstrual cycle treatment period, and 3 menstrual cycle observation period. If pregnant during the study, participants will take the herbal medicine for implantation for about 15 days. In this study, the primary outcome will be the clinical pregnancy rate, whereas the secondary outcome will include the implantation rate, ongoing pregnancy rate, and live birth rate.Ultimately, this study will provide clinical data regarding the effectiveness and safety of KM treatment for females with unexplained infertility and important evidence for establishing standard KM treatments for unexplained infertility. Moreover, we will identify the most cost-effective way to treat unexplained infertility. TRIAL REGISTRATION IDENTIFIER: Korean Clinical Trial Registry (CRIS), Republic of Korea: KCT0002235. Date: February 21, 2017 (retrospectively registered).
[Mh] Termos MeSH primário: Terapia por Acupuntura/métodos
Infertilidade Feminina/terapia
Medicina Tradicional Coreana/economia
Taxa de Gravidez
Técnicas de Reprodução Assistida/economia
[Mh] Termos MeSH secundário: Análise de Variância
Análise Custo-Benefício
Feminino
Seres Humanos
Infertilidade Feminina/epidemiologia
Medicina Tradicional Coreana/métodos
Segurança do Paciente
Fitoterapia/economia
Fitoterapia/métodos
Gravidez
Estudos Prospectivos
República da Coreia
Medição de Risco
Estatísticas não Paramétricas
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009360


  6 / 8716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29374883
[Au] Autor:Lyu XD; Qiao J
[Ad] Endereço:Center of Reproductive Medicine, Peking University Third Hospital, Beijing 100191, China.
[Ti] Título:[Analysis of pregnancy outcomes of polycystic ovary syndrome patients after frozen embryo transfer].
[So] Source:Zhonghua Fu Chan Ke Za Zhi;53(1):31-34, 2018 Jan 25.
[Is] ISSN:0529-567X
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To investigate pregnancy outcomes of the patients with polycystic ovary syndrome (PCOS) after frozen embryo transfer (FET) . Data of 2 367 PCOS patients received in vitro fertilization-embryo transfer [including fresh embryo transfer (fET) and FET] from January 2009 to December 2015 in Peking University Third Hospital were evaluated retrospectively. The basal characteristics, pregnancy complications and outcomes were analyzed, then identified the relative factors followed. Totally 2 367 patients received in vitro fertilization-embryo transfer: 1 106 were treated with fET, and the rest 1 261 cases were treated with FET. The incidence of gestational diabetes mellitus (GDM) was lower in FET group [4.04%(51/1 261) versus 6.15%(68/1 106)], the difference was statistically significant ( 0.05). Singletons born after FET had higher birth weight than fET [(3 406±548) versus (3 360±533) g], the difference was statistically significant ( 0.05). There was no difference of other pregnancy complications between the two groups (all 0.05). fET was an independent risk factor for GDM (adjusted 1.570, 95% 1.075-2.294). Compared with fET, FET could decrease the risk of GDM and receive better neonatal outcomes in patients with PCOS.
[Mh] Termos MeSH primário: Criopreservação
Transferência Embrionária/métodos
Fertilização In Vitro/métodos
Infertilidade Feminina/terapia
Síndrome do Ovário Policístico/terapia
Complicações na Gravidez/epidemiologia
Resultado da Gravidez
[Mh] Termos MeSH secundário: Peso ao Nascer
Diabetes Gestacional/epidemiologia
Feminino
Seres Humanos
Incidência
Infertilidade Feminina/etiologia
Síndrome do Ovário Policístico/complicações
Gravidez
Taxa de Gravidez
Estudos Retrospectivos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0529-567X.2018.01.007


  7 / 8716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29374882
[Au] Autor:Li Y; Tan JQ; Mai ZY; Yang DZ
[Ad] Endereço:Center for Reproductive Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
[Ti] Título:[Value of anti-Müllerian hormone in predicting pregnant outcomes of polycystic ovary syndrome patients undergone assisted reproductive technology].
[So] Source:Zhonghua Fu Chan Ke Za Zhi;53(1):23-30, 2018 Jan 25.
[Is] ISSN:0529-567X
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:Explore the value of anti-Müllerian hormone (AMH) in predicting pregnant outcomes of polycystic ovary syndrome (PCOS) patients undergone assisted reproductive technology. The study totally recruited 1 697 patients who underwent the first in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycle in Sun Yat-sen Memorial Hospital from the January 2014 to December 2015. The patients were divided into two groups based on the age<35 ( 758) and ≥35 years old ( 939) , compare the basic data and pregnant outcomes of controlled ovarian hyerstimulation. Spearman correlation method was conducted to analyze the relations between AMH and clinical outcomes. The logistic regression method and partial correlation analysis were used to judge the main factors which determine pregnancy outcomes by controlled the confounding factors. The receiver operating characteristic curve (ROC) was used to evaluate the predictive sensitivity and specificity of AMH. In the group of PCOS patient younger than 35 years, AMH were correlated with the number of antral follicles ( 0.388) and retrieved oocytes ( 0.235) . When the effect of total dosage and starting dosage of gonadotropin were controlled, AMH was still significantly associated with the number of retrieved oocytes ( 0.05) . AMH had no predictive value for the clinical pregnancy of PCOS patient younger than 35 years (area under ROC curve=0.481, 0.768) . In the group of PCOS patient≥35 years old, AMH were correlated with the number of antral follicles ( 0.450) , retrieved oocytes ( 0.399) , available embryo ( 0.336) and high quality embryo ( 0.235) . When the effect of total dosage and starting dosage of gonadotropin were controlled, the correlations were still significant between those indexes (all 0.05) . AMH had no predictive value for the clinical pregnancy of PCOS patient ≥35 years old (area under ROC curve=0.535, 0.560) . However, the clinical pregnancy rate of the group of PCOS patient ≥35 years old was slightly higher than the control group ( 0.062) . AMH has no predictive value for the pregnancy outcome of PCOS patient. The pregnancy rate of PCOS patient ≥35 years old is slightly higher than the younger group, because the PCOS patient may have better ovarian reserve.
[Mh] Termos MeSH primário: Hormônio Antimülleriano/sangue
Fertilização In Vitro/métodos
Síndrome do Ovário Policístico/sangue
Síndrome do Ovário Policístico/metabolismo
Síndrome do Ovário Policístico/terapia
Resultado da Gravidez
Técnicas de Reprodução Assistida
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Hormônio Antimülleriano/metabolismo
Feminino
Seres Humanos
Folículo Ovariano/metabolismo
Gravidez
Taxa de Gravidez
Prognóstico
Curva ROC
Sensibilidade e Especificidade
Injeções de Esperma Intracitoplásmicas
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
80497-65-0 (Anti-Mullerian Hormone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0529-567X.2018.01.006


  8 / 8716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390463
[Au] Autor:Ng KK; Rozen G; Stewart T; Agresta F; Polyakov A
[Ad] Endereço:Melbourne Medical School, University of Melbourne.
[Ti] Título:A double-blinded, randomized, placebo-controlled trial assessing the effects of nifedipine on embryo transfer: Study protocol.
[So] Source:Medicine (Baltimore);96(51):e9194, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Implantation failure is the main factor affecting the success rate of in vitro fertilization (IVF) procedures. Studies have reported that uterine contractions (UCs) at the time of embryo transfer (ET) were inversely related to implantation and pregnancy rate, hence reducing the success of IVF treatment. Various pharmacological agents, with the exception of calcium channel blocker (CCB), have been investigated to reduce UC. In this regard, we are presenting a proposal for a double-blind randomized placebo-controlled trial. The trial aims to determine whether nifedipine, a CCB with potent smooth muscle relaxing activity and an excellent safety profile, can improve the outcome of ET. METHODS AND ANALYSES: We will recruit 100 infertile women into one of 2 groups: placebo (n = 50) and nifedipine 20 mg (n = 50). Study participants will be admitted 30 minutes prior to ET and given either tablet after their baseline vital signs have been recorded. They will then undergo ET and be observed for adverse events for another 30 minutes post-ET. The primary outcome will be implantation rate and clinical pregnancy rate. Secondary outcomes include adverse events, miscarriage and pregnancy, and neonatal outcomes. Resulting data will then be analyzed using t test, Chi-square test, and multivariate test to compare outcomes between the 2 groups for any statistical significance. This protocol has been designed in accordance with the SPIRIT 2013 Guidelines.
[Mh] Termos MeSH primário: Transferência Embrionária
Fertilização In Vitro/efeitos dos fármacos
Infertilidade Feminina/tratamento farmacológico
Nifedipino/administração & dosagem
Resultado da Gravidez
Taxa de Gravidez
[Mh] Termos MeSH secundário: Distribuição de Qui-Quadrado
Método Duplo-Cego
Feminino
Seres Humanos
Idade Materna
Análise Multivariada
Nifedipino/efeitos adversos
Gravidez
Medição de Risco
Tocolíticos/administração & dosagem
Tocolíticos/efeitos adversos
Vitória
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Tocolytic Agents); I9ZF7L6G2L (Nifedipine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009194


  9 / 8716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29369190
[Au] Autor:Zhang T; Li Z; Ren X; Huang B; Zhu G; Yang W; Jin L
[Ad] Endereço:Reproductive Medicine Center, Tongji Hospital, Tongji Medicine College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
[Ti] Título:Endometrial thickness as a predictor of the reproductive outcomes in fresh and frozen embryo transfer cycles: A retrospective cohort study of 1512 IVF cycles with morphologically good-quality blastocyst.
[So] Source:Medicine (Baltimore);97(4):e9689, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To evaluate the relationship between endometrial thickness during fresh in vitro fertilization (IVF) cycles and the clinical outcomes of subsequent frozen embryo transfer (FET) cycles.FET cycles using at least one morphological good-quality blastocyst conducted between 2012 and 2013 at a university-based reproductive center were reviewed retrospectively. Endometrial ultrasonographic characteristics were recorded both on the oocyte retrieval day and on the day of progesterone supplementation in FET cycles. Clinical pregnancy rate, spontaneous abortion rate, and live birth rate were analyzed.One thousand five hundred twelve FET cycles was included. The results showed that significant difference in endometrial thickness on day of oocyte retrieval (P = .03) was observed between the live birth group (n = 844) and no live birth group (n = 668), while no significant difference in FET endometrial thickness was found (P = .261) between the live birth group and no live birth group. For endometrial thickness on oocyte retrieval day, clinical pregnancy rate ranged from 50.0% among patients with an endometrial thickness of ≤6 mm to 84.2% among patients with an endometrial thickness of >16 mm, with live birth rate from 33.3% to 63.2%. Multiple logistic regression analysis of factors related to live birth indicated endometrial thickness on oocyte retrieval day was associated with improved live birth rate (OR was 1.069, 95% CI: 1.011-1.130, P = .019), while FET endometrial thickness did not contribute significantly to pregnancy outcomes following FET cycles. The ROC curves revealed the cut-off points of endometrial thickness on oocyte retrieval day was 8.75 mm for live birth.Endometrial thickness during fresh IVF cycles was a better predictor of endometrial receptivity in subsequent FET cycles than FET cycle endometrial thickness. For those females with thin endometrium in fresh cycles, additional estradiol stimulation might be helpful for adequate endometrial development.
[Mh] Termos MeSH primário: Blastocisto
Transferência Embrionária/métodos
Endométrio/diagnóstico por imagem
Fertilização In Vitro/estatística & dados numéricos
Recuperação de Oócitos/métodos
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Modelos Logísticos
Idade Materna
Gravidez
Taxa de Gravidez
Curva ROC
Estudos Retrospectivos
Ultrassonografia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009689


  10 / 8716 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771155
[Au] Autor:Sükür YE; Özmen B; Özdemir ED; Seval MM; Kalafat E; Sönmezer M; Berker B; Aytaç R; Atabekoglu CS
[Ad] Endereço:Department of Obstetrics and Gynecology, Ankara University School of Medicine, Kadin Hastaliklari ve Dogum AD, 06100 Cebeci, Ankara, Turkey.
[Ti] Título:Final oocyte maturation with two different GnRH agonists in antagonist co-treated cycles at risk of ovarian hyperstimulation syndrome.
[So] Source:Reprod Biomed Online;34(1):5-10, 2017 Jan.
[Is] ISSN:1472-6491
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Triptorelin 0.2 mg and leuprolide 1 mg subcutaneous injections for triggering final follicular maturation were compared in patients with a high risk for ovarian hyperstimulation syndrome (OHSS). Infertile patients treated with GnRH antagonist protocol between January 2014 and March 2016 were recruited. Patients with high serum oestradiol levels on HCG day (>3000 pg/ml) indicating a risk of OHSS consisted of the study groups (A and B). Patients with serum oestradiol levels less than 3000 pg/ml consisted of the control group (C). A single injection of 0.2 mg triptorelin, 1 mg leuprolide and 10000 IU HCG were administered for final oocyte triggering in groups A (n = 63), B (n = 74) and C (n = 131), respectively. Demographic parameters were comparable between the groups. No cases of severe or moderate OHSS occurred in any group. The clinical pregnancy rates were 31.7%, 37.8% and 32.8% in groups A, B and C, respectively. Both injections had comparable efficacy in clinical outcome and OHSS risk. Regardless of preferred drug, GnRH agonist trigger for final oocyte maturation seems to be safe for patients with high OHSS risk, and can be safely used in fresh embryo transfer cycles.
[Mh] Termos MeSH primário: Hormônio Liberador de Gonadotropina/agonistas
Hormônio Liberador de Gonadotropina/antagonistas & inibidores
Oócitos/citologia
Síndrome de Hiperestimulação Ovariana/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Estradiol/sangue
Feminino
Antagonistas de Hormônios/uso terapêutico
Seres Humanos
Infertilidade Feminina/terapia
Infertilidade Masculina/terapia
Leuprolida/administração & dosagem
Masculino
Oócitos/efeitos dos fármacos
Oogênese
Indução da Ovulação
Gravidez
Taxa de Gravidez
Estudos Retrospectivos
Risco
Injeções de Esperma Intracitoplásmicas
Pamoato de Triptorrelina/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hormone Antagonists); 33515-09-2 (Gonadotropin-Releasing Hormone); 4TI98Z838E (Estradiol); 57773-63-4 (Triptorelin Pamoate); EFY6W0M8TG (Leuprolide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE



página 1 de 872 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde